Disulfiram in Rheumatoid Arthritis

NCT ID
NCT07534332
Registry status
Not yet recruiting
Study type
Interventional
Phase
Phase 2
Sponsor
University of Oklahoma
Conditions
Inflammation, Obesity, Rheumatoid Arthritis

Overview

ClinicalTrials.gov lists this study as Not yet recruiting.

Official title: Therapeutic Targeting of Gasdermin D-Mediated Pyroptosis to Attenuate Joint Inflammation in Rheumatoid Arthritis

Enrollment: 20 participants (Estimated).

What is being studied

  • Intervention: Acids, Acyclic
  • Intervention: Carbamates
  • Intervention: Carboxylic Acids
  • Intervention: Disulfides
  • Intervention: Disulfiram
  • Drug: Disulfiram (DSF)
  • Intervention: Ditiocarb
  • Intervention: Organic Chemicals
  • Drug: Placebo
  • Intervention: Sulfides
  • Intervention: Sulfur Compounds
  • Intervention: Thiocarbamates

Who may be eligible

Ages
18 Years to 75 Years
Sex
All
Healthy volunteers accepted
No

ClinicalTrials.gov lists the following eligibility criteria.

Inclusion Criteria: Age 18-75 years Body mass index (BMI) ≥25 kg/m² Diagnosis of rheumatoid arthritis (RA) according to ACR/EULAR classification criteria Active disease defined as Clinical Disease Activity Index (CDAI) \>10 Stable disease-modifying antirheumatic drug (DMARD) therapy for ≥3 months prior to enrollment Willingness to abstain from alcohol for the duration of the study Ability and willingness to comply with study procedures \- Exclusion Criteria: Significant liver dysfunction (ALT or AST \>2.5× upper limit of normal) Current or recent alcohol dependence (based on screening, e.g., AUDIT) Known hypersensitivity to disulfiram or other thiuram derivatives Pregnancy or breastfeeding Severe cardiovascular disease (e.g., myocardial infarction, arrhythmia, coronary occlusion) Severe psychiatric illness (e.g., psychosis, suicidal ideation) Neurologic disorders (e.g., epilepsy, peripheral neuropathy, cerebral damage) Chronic or acute renal disease (e.g., nephritis) Hepatic cirrhosis or hepatic insufficiency Use of contraindicated medications (e.g., metronidazole, phenytoin, paraldehyde, alcohol-containing preparations, warfarin) Other autoimmune diseases or active/chronic infections Diabetes mellitus or hypothyroidism Allergy to topical iodine Any condition that, in the opinion of the investigator, would pose undue risk or interfere with study participation

Study locations

1 study location is listed.

Site recruitment status is not specified in the registry data for these locations.

Countries: United States

  • Oklahoma, United States: 1

Sample of listed locations

  • University of Oklahoma Health Campus — Oklahoma City, Oklahoma, 73104, United States — Site recruitment status not specified in the registry data

Study details

Start date
September 1, 2026
Primary completion date
April 30, 2027
Completion date
April 30, 2028
First posted
April 16, 2026
Collaborators
Presbyterian Health Foundation

Source and update information

Source
ClinicalTrials.gov
NCT ID
NCT07534332
Registry last updated
July 27, 2026
QualifiedStudies registry data refreshed
October 2, 2026
QualifiedStudies record fetched
October 2, 2026

View NCT07534332 on ClinicalTrials.gov

Trial information can change. Confirm current study details with the study team or the registry.

About joining clinical research

Find clinical trials you may match with

QualifiedStudies can help you search for research opportunities related to your health. Availability of this specific study through QualifiedStudies has not been established.

Find clinical trials you may match with | Clinical trial FAQ